feed,title,long_url,short_url
Benzinga,"Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant",https://benzinga.com/general/biotech/21/07/22081557/aprea-stock-pops-as-eprenetapopt-combo-regime-shows-58-relapse-free-survival-79-overall-survival-,https://j.mp/3BtPKa7
Benzinga,Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease,https://benzinga.com/general/biotech/21/07/22081061/dicerna-posts-updated-data-from-belcesiran-early-stage-study-for-genetic-liver-disease,https://j.mp/3kKGMiT
